Claims
- 1. A compound of formula (I) or a salt thereof: ##STR5## in which R.sup.1 is oxadiazole;
- R.sup.2 and R.sup.3 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkenyl, C.sub.1-6 alkoxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylOC.sub.1-6 alkyl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, NR.sup.10 R.sup.11 where R.sup.10 and R.sup.11 are independently hydrogen or C.sub.1-6 alkyl;
- R.sup.4 is hydrogen or C.sub.1-6 alkyl;
- R.sup.5 and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl;
- A is CONH;
- B is oxygen, sulphur, CR.sup.12 R.sup.13 or NR.sup.14 where R.sup.12, R.sup.13 and R.sup.14 are independently hydrogen or C.sub.1-6 alkyl;
- m is 1, 2 or 3; and
- n is 1, 2 or 3.
- 2. A compound according to claim 1 in which R.sup.2 is C.sub.1-6 alkyl.
- 3. A compound according to claim 1 in which R.sup.3 is hydrogen.
- 4. A compound according to claim 1 in which n is 1 and m is 2.
- 5. A compound according to claim 1 which is:
- N-(2,3-Dihydro-1'-methylspiro�4H-benzopyran-6-yl-4,4'-piperidine!)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-(2,3-Dihydrospiro�4H-benzopyran-6-yl-4,4'-piperidine!)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-(2,3-Dihydro-1-methylspiro�benzofuran-5-yl-3,4'-piperidine!)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-(2,3-Dihydro-1'-methylspiro�benzothiophen-5-yl-3,4'-piperidine!)-2 '-methyl-4'-(5-methyl-1,2,4-oxadiazol-5-yl)biphenyl-4-carboxamide,
- N-(1,2,3,5,6,7-Hexahydro-1-methylspiro�4H-azepine-4,3'(2H)-benzofuran-5'-yl!)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- or pharmaceutically acceptable salts thereof.
- 6. A pharmaceutical composition which comprises a compound of claim 1 in association with a pharmaceutically acceptable carrier or excipient.
- 7. A method of treating depression, anxiety, which method involves treating a patient in need thereof with a therapeutically effective amount of a compound of formula (I) as described in claim 1.
- 8. A process for the preparation of a compound of formula (I), as defined in claim 1, which comprises:
- coupling a compound of formula (II): ##STR6## with a compound of formula (III): ##STR7## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, B, m and n are as defined in formula (I), as defined in claim 1, and R.sup.15 and R.sup.16 are functional groups which when coupled form the --CONH--linkage;
- and then optionally forming a pharmaceutically acceptable salt.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9421003 |
Oct 1994 |
GBX |
|
CROSS-REFERENCE
This application is a 371 of PCT/EP95/03945 filed Oct. 5,1995.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP95/03945 |
10/5/1995 |
|
|
4/16/1997 |
4/16/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/11934 |
4/25/1996 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5756496 |
Ham et al. |
May 1998 |
|
5817833 |
Gaster |
Oct 1998 |
|
Non-Patent Literature Citations (1)
Entry |
J. W. Clitherow et al., Journal of Medicinal Chemistry, vol. 37, No. 15, pp. 2253-2257 (1994). |